Skip to main content
NCBI home page
Journal of Neurology, Neurosurgery, and Psychiatry logoLink to Journal of Neurology, Neurosurgery, and Psychiatry
. 1977 Dec;40(12):1142–1146. doi: 10.1136/jnnp.40.12.1142

Bromocriptine alone or associated with L-dopa plus benserazide in Parkinson's disease.

T A Caraceni, I Celano, E Parati, F Girotti
PMCID: PMC492936  PMID: 591982

Abstract

Twenty-six patients affected by Parkinson's disease were treated with a 2-Br-alpha-ergocriptine (CB 154): 14 cases were given CB 154 alone, and 12 were given CB 154 along with L-dopa plus benserazide (Madopar). Both CB 154 and combined therapy (CB 154+Madopar) induced a significant improvement in total disability score, tremor, rigidity, akinesia, self-sufficiency, and some motor performance tests (dynamic tests). No significant difference was found between results obtained with CB 154 therapy and with Madopar treatment, while the improvement induced by combined therapy (CB 154+Madopar) was significantly higher than that obtained by Madopar alone. The averse reactions caused by CB 154 alone or associated with Madopar are similar to those observed during other dopaminergic treatment. CB 154 alone or combined with Madopar appears to be a useful advance in the management of Parkinson's disease.

Full text

PDF
1142

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Billeter E., Flückinger E. Evidence for a luteolytic function of prolactin in the intact cyclic rat using 2-Br-alpha-Ergokryptine (CB 154). Experientia. 1971 Apr 15;27(4):464–465. doi: 10.1007/BF02137315. [DOI] [PubMed] [Google Scholar]
  2. Calne D. B., Teychenne P. F., Claveria L. E., Eastman R., Greenacre J. K., Petrie A. Bromocriptine in Parkinsonism. Br Med J. 1974 Nov 23;4(5942):442–444. doi: 10.1136/bmj.4.5942.442. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Corrodi H., Fuxe K., Hökfelt T., Lidbrink P., Ungerstedt U. Effect of ergot drugs on central catecholamine neurons: evidence for a stimulation of central dopamine neurons. J Pharm Pharmacol. 1973 May;25(5):409–412. doi: 10.1111/j.2042-7158.1973.tb10037.x. [DOI] [PubMed] [Google Scholar]
  4. Flückiger E., Wagner H. R. 2-Br-alpha-Ergokryptin: Beeinflussung von Fertilität und Laktation bei der Ratte. Experientia. 1968 Nov 15;24(11):1130–1131. doi: 10.1007/BF02147804. [DOI] [PubMed] [Google Scholar]
  5. Gautier J. C., Durand J. P. Traitement des syndromes parkinsoniens par la bromocriptine. Nouv Presse Med. 1977 Jan 22;6(3):171–174. [PubMed] [Google Scholar]
  6. Gerlach J. Effect of CB 154 (2-bromo-alpha-ergocryptine) on paralysis agitans compared with Madopar in a double-blind, cross-over trial. Acta Neurol Scand. 1976 Mar;53(3):189–200. doi: 10.1111/j.1600-0404.1976.tb04337.x. [DOI] [PubMed] [Google Scholar]
  7. Goldstein M., Battista A. F., Miyamoto T. Modification of involuntary movements by centrally acting drugs. Adv Neurol. 1975;9:299–305. [PubMed] [Google Scholar]
  8. Kartzinel R., Shoulson I., Calne D. B. Studies with bromocriptine. Part 2. Double-blind comparison with levodopa in idiopathic parkinsonism. Neurology. 1976 Jun;26(6 Pt 1):511–513. doi: 10.1212/wnl.26.6.511. [DOI] [PubMed] [Google Scholar]
  9. Kartzinel R., Shoulson I., Calne D. B. Studies with bromocriptine: III. Concomitant administration of caffeine to patients with idiopathic parkinsonism. Neurology. 1976 Aug;26(8):741–743. doi: 10.1212/wnl.26.8.741. [DOI] [PubMed] [Google Scholar]
  10. Kartzinel R., TEYCHENNE P., Gillespie M. M., Perlow M., Gielen A. C., Sadowsky D. A., Calne D. B. Bromocriptine and levodopa (with or without carbidopa) in parkinsonism. Lancet. 1976 Aug 7;2(7980):272–275. doi: 10.1016/s0140-6736(76)90728-5. [DOI] [PubMed] [Google Scholar]
  11. Kartznel R., Calne D. B. Studies with bromocriptine. Part 1. "On-off" phenomena. Neurology. 1976 Jun;26(6 Pt 1):508–510. doi: 10.1212/wnl.26.6.508. [DOI] [PubMed] [Google Scholar]
  12. Lieberman A., Kupersmith M., Estey E., Goldstein M. Treatment of parkinson's disease with bromocriptine. N Engl J Med. 1976 Dec 16;295(25):1400–1404. doi: 10.1056/NEJM197612162952504. [DOI] [PubMed] [Google Scholar]
  13. Lieberman A., Miyamoto T., Battista A. F., Goldstein M. Studies on the antiparkinsonism efficacy of lergotrile. Neurology. 1975 May;25(5):459–462. doi: 10.1212/wnl.25.5.459. [DOI] [PubMed] [Google Scholar]
  14. Lieberman A., Zolfaghari M., Boal D., Hassouri H., Vogel B., Battista A., Fuxe K., Goldstein M. The antiparkinsonian efficacy of bromocriptine. Neurology. 1976 May;26(5):405–409. doi: 10.1212/wnl.26.5.405. [DOI] [PubMed] [Google Scholar]
  15. Miyamoto T., Battista A., Goldstein M., Fuxe K. Long-lasting anti-tremor induced by 2-Br-alpha-ergocryptine in monkeys. J Pharm Pharmacol. 1974 Jun;26(6):452–454. doi: 10.1111/j.2042-7158.1974.tb09312.x. [DOI] [PubMed] [Google Scholar]
  16. Parkes J. D., Marsden C. D., Donaldson I., Galea-Debono A., Walters J., Kennedy G., Asselman P. Bromocriptine treatment in Parkinson's disease. J Neurol Neurosurg Psychiatry. 1976 Feb;39(2):184–193. doi: 10.1136/jnnp.39.2.184. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Journal of Neurology, Neurosurgery, and Psychiatry are provided here courtesy of BMJ Publishing Group

RESOURCES